Advertisement
MDGL vs PTN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a StrongBuy and PTN is a Hold.
MDGL's RSI Indicator climbs out of oversold territory
The RSI Indicator for MDGL moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 27 of the 33 cases the stock moved higher. This puts the odds of a move higher at 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 65 cases where MDGL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on MDGL as a result. In 68 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for MDGL just turned positive on November 09, 2026. Looking at past instances where MDGL's MACD turned positive, the stock continued to rise in 29 of 39 cases over the following month. The odds of a continued upward trend are 74%.
Following a +1.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in 219 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
MDGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for MDGL moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for MDGL entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.630) is normal, around the industry mean (3.498). P/E Ratio (-28.565) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.443) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 25 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. MDGL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Momentum Indicator for PTN turns positive, indicating new upward trend
PTN saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned positive. In 72 of the 82 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PTN's RSI Indicator exited the oversold zone, 27 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for PTN just turned positive on November 03, 2026. Looking at past instances where PTN's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +26.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where PTN advanced for three days, in 182 of 218 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PTN broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PTN entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.668) is normal, around the industry mean (3.498). P/E Ratio (-2.118) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.507) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. PTN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PTN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MDGL | PTN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 41 Fair valued | |
PROFIT vs RISK RATING 1..100 | 25 | 100 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 72 | 81 | |
P/E GROWTH RATING 1..100 | 17 | 98 | |
SEASONALITY SCORE 1..100 | 75 | 38 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDGL's Valuation (15) in the Pharmaceuticals Other industry is in the same range as PTN (41) in the Biotechnology industry. This means that MDGL’s stock grew similarly to PTN’s over the last 12 months.
MDGL's Profit vs Risk Rating (25) in the Pharmaceuticals Other industry is significantly better than the same rating for PTN (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than PTN’s over the last 12 months.
MDGL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as PTN (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to PTN’s over the last 12 months.
MDGL's Price Growth Rating (72) in the Pharmaceuticals Other industry is in the same range as PTN (81) in the Biotechnology industry. This means that MDGL’s stock grew similarly to PTN’s over the last 12 months.
MDGL's P/E Growth Rating (17) in the Pharmaceuticals Other industry is significantly better than the same rating for PTN (98) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than PTN’s over the last 12 months.
| MDGL | PTN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 82% | 1 day ago 79% |
| Stochastic ODDS (%) | 1 day ago 78% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 76% | 1 day ago 88% |
| MACD ODDS (%) | 1 day ago 74% | 1 day ago 78% |
| TrendWeek ODDS (%) | 1 day ago 77% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 77% | 1 day ago 90% |
| Advances ODDS (%) | 16 days ago 75% | 3 days ago 83% |
| Declines ODDS (%) | 6 days ago 80% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 74% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 70% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MDGL’s FA Score shows that 3 FA rating(s) are green while PTN’s FA Score has 0 green FA rating(s).
- MDGL’s FA Score: 3 green, 2 red.
- PTN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MDGL’s TA Score shows that 6 TA indicator(s) are bullish while PTN’s TA Score has 4 bullish TA indicator(s).
- MDGL’s TA Score: 6 bullish, 3 bearish.
- PTN’s TA Score: 4 bullish, 4 bearish.
Price Growth
MDGL (@Biotechnology) experienced а +8.14% price change this week, while PTN (@Biotechnology) price change was +13.95% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
MDGL is expected to report earnings on Feb 25, 2027.
PTN is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
PTN and
Correlation & Price change
A.I.dvisor indicates that over the last year, PTN has been loosely correlated with FATE. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if PTN jumps, then FATE could also see price increases.
| Ticker / NAME | Correlation To PTN | 1D Price Change % | ||
|---|---|---|---|---|
| PTN | 100% | -0.44% | ||
| FATE - PTN | 41% Loosely correlated | -9.32% | ||
| MLTX - PTN | 35% Loosely correlated | +7.56% | ||
| VTGN - PTN | 35% Loosely correlated | +2.57% | ||
| MDGL - PTN | 32% Poorly correlated | +0.10% | ||
| RYTM - PTN | 30% Poorly correlated | -1.57% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EMXC | 90.91 | 2.86 | +3.25% |
| iShares MSCI Emerging Markets ex China ETF (EMXC) | |||
| TSME | 45.61 | 0.36 | +0.80% |
| Thrivent Small-Mid Cap Equity ETF (TSME) | |||
| MCHS | 34.88 | 0.28 | +0.80% |
| Matthews China Innovators Active ETF (MCHS) | |||
| XFEB | 38.47 | 0.16 | +0.41% |
| FT Vest U.S. Equity Enhance & Moderate Buffer ETF - February (XFEB) | |||
| CANC | 42.29 | -0.39 | -0.91% |
| Tema Oncology ETF (CANC) | |||